Biovail reduces quarterly guidance

Article Abstract:

Mississauga-based Biovail Corp. has cut its third-quarter guidance, after a fatal traffic accident involving a tractor-trailer loaded with millions of the company's anti-depression pills. The wreck prevented a shipment of Wellbutrin XL tablets worth $15-million to $20-million from reaching GlaxoSmithKline PLC, which is Biovail's marketing partner in the venture.

Production management

---

Biovail beats investor anxiety

Article Abstract:

Biovail Corp. saw its share value increase 7.59% after the company's new antidepressant drug was tentatively approved in the U.S. Biovail's shares closed at 4.69 Canadian dollars.

---

FDA's tramadol decision boosts Biovail outlook

Article Abstract:

Food and Drug Administration approves sale of Tramadol ER pain reliever. The approval increased company's share price by 6%.

Product development, Marketing procedures, Government regulation, Medicinal and Botanical Manufacturing, Medicinals and botanicals, Analgesics & Antipyretics NEC, Marketing, Licensing, certification and accreditation, Company marketing practices, Analgesics, Tramadol (Medication)

Similar abstracts:

• Abstracts: First Marathon's Cartaway debacle. First Marathon stock halted after leak on talks. Agency finds dirty money
• Abstracts: Rising oil prices spark hopes for faster sector comeback. Former Gulf Canada head got $5.61-million sendoff in 1998
• Abstracts: Brewers sweeten faltering deal. Half of Canadian firms to boost marketing budgets
• Abstracts: Amaranth managed to trample the most revered investing principles. MDS board adds hedge fund manager; may be first step to revamp
• Abstracts: GM adds rebates to incentives. Creditors give thumbs up to Stelco restructuring. Stelco plan goes to a vote Friday

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.